PE20210155A1 - Anticonceptivos de profarmacos de progestina de accion mas prolongada - Google Patents

Anticonceptivos de profarmacos de progestina de accion mas prolongada

Info

Publication number
PE20210155A1
PE20210155A1 PE2020000487A PE2020000487A PE20210155A1 PE 20210155 A1 PE20210155 A1 PE 20210155A1 PE 2020000487 A PE2020000487 A PE 2020000487A PE 2020000487 A PE2020000487 A PE 2020000487A PE 20210155 A1 PE20210155 A1 PE 20210155A1
Authority
PE
Peru
Prior art keywords
progestin
alkyl
contraceptives
drugs
etonogestrel
Prior art date
Application number
PE2020000487A
Other languages
English (en)
Inventor
Gulzar Ahmed
Frederick Meece
Hareesh Nair
Klaus Nickisch
Original Assignee
Evestra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evestra Inc filed Critical Evestra Inc
Publication of PE20210155A1 publication Critical patent/PE20210155A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere se refiere a compuestos de progestina que tienen tasas de liberacion prolongada y que se pueden usar sin un estrogeno para producir un estado anticonceptivo. Estos compuestos presentan la formula I (Figura 1) donde la progestina es levonorgestrel o etonogestrel; y R1, R2 se combinan para formar un anillo de 3 a 7 miembros fusionado con hasta dos heteroatomos, o cada R1, R2 es H, alquilo, cicloalquilo, fenilo, arilo, heteroarilo, acilo, ciano, halogeno, OH, alcoxi, alquil-sulfonilo o sulfonamida; y presenta la formula II (Figura 2) en donde la progestina es levonorgestrel o etonogestrel; hAr es piridina, pirimidina, pirazina u oxazol; R1, R2 se combinan para formar un anillo de 3 a 7 miembros fusionado con hasta dos heteroatomos, o cada R1, R2 es H, alquilo, cicloalquilo, fenilo, arilo, heteroarilo, acilo, ciano, halogeno, OH, alcoxi, alquilsulfonilo o sulfonamida.
PE2020000487A 2017-10-19 2018-09-14 Anticonceptivos de profarmacos de progestina de accion mas prolongada PE20210155A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574445P 2017-10-19 2017-10-19
PCT/US2018/051026 WO2019078983A1 (en) 2017-10-19 2018-09-14 CONTRACEPTIVES OF PROGESTINE PRODRANT WITH EXTENDED ACTION

Publications (1)

Publication Number Publication Date
PE20210155A1 true PE20210155A1 (es) 2021-01-26

Family

ID=66169066

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000487A PE20210155A1 (es) 2017-10-19 2018-09-14 Anticonceptivos de profarmacos de progestina de accion mas prolongada

Country Status (10)

Country Link
US (1) US10624903B2 (es)
EP (1) EP3697421B1 (es)
AU (1) AU2018353858A1 (es)
BR (1) BR112020007673A2 (es)
CL (1) CL2020001028A1 (es)
CO (1) CO2020003537A2 (es)
EC (1) ECSP20026239A (es)
MX (1) MX2020003470A (es)
PE (1) PE20210155A1 (es)
WO (1) WO2019078983A1 (es)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753793A (en) * 1953-07-17 1956-08-01 Schering Corp Aryloxy esters of testosterone, and therapeutic compositions thereof
DE1018416B (de) * 1953-07-17 1957-10-31 Schering Corp Verfahren zur Herstellung von Aryloxyestern des Testosterons
US3051731A (en) * 1960-04-11 1962-08-28 Parke Davis & Co 5, 6, 7, 8-tetrahydro-1-methyl-2-naphthoxy-acetic acid esters of hydroxy steroids
GB1069779A (en) * 1965-05-05 1967-05-24 Schering Ag 17ª‡-ethynyl-18-methyl-19-nor-testosterone esters and process for their manufacture
US3461118A (en) 1966-10-17 1969-08-12 Syntex Corp 3beta-tetrahydrofuranyloxy - and 3beta-tetrahydropyranyloxyestra - 4,9(10) - dienes and -4,9(10),11-trienes,their preparation and intermediates thereof
GB1355663A (en) * 1970-06-17 1974-06-05 Theramex 19-nortestosterone 17- -p-substituted phenoxy-acetates
US4507290A (en) * 1981-04-07 1985-03-26 World Health Organization Esters of 17 α-ethynyl 19-nor-testosterone and 17 α-ethynyl-18-homo-19-nor-testosterone and pharmaceutical compositions containing the same
GB8313921D0 (en) * 1983-05-19 1983-06-22 World Health Org Contraceptive compositions
US4615835A (en) 1983-11-17 1986-10-07 Stiftung Deutsches Krebsforschungs Zentrum Steroid esters of N-(2-halogenethyl)-N-nitroso-carbamoylamino and acids and peptides therefore, as well as method for preparing them
DE3511588A1 (de) * 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Waessrige kristallsuspension von steroidglykoestern
SE8802402D0 (sv) 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
DE4029499A1 (de) 1990-09-18 1992-03-19 Boehringer Mannheim Gmbh Neue 17-(beta)-oestradiolderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE4447714C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur Hormonsubstitutions-Therapie
US5705495A (en) 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
FR2774989B1 (fr) 1998-02-18 2000-03-17 Adir Nouveaux cytotoxiques derives de l'oestradiol
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
FR2801218B1 (fr) 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6956031B2 (en) 2002-03-27 2005-10-18 Schering Aktiengesellschaft 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
TW200400041A (en) * 2002-05-30 2004-01-01 Akzo Nobel Nv Use of new etonogestrel esters
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070135375A1 (en) 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
EP2162432A2 (en) 2007-06-29 2010-03-17 Gilead Sciences, Inc. Antiviral compounds
US20100061976A1 (en) 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
EP2419398A4 (en) * 2009-04-14 2012-11-28 Infiniton Ab PRO-BET WITH BETA-KETO-CARBOXYLIC ACID, BETA-KETO-CARBOXYLIC ACID SALT OR BETA-KETO-CARBOXYLIC ACID ESTERS FOR ACTIVE INHIBITION
CN104130172B (zh) 2009-12-14 2016-05-18 罗门哈斯电子材料有限公司 磺酰光酸产生剂和包含该磺酰光酸产生剂的光刻胶
CN102079771B (zh) 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法
CN102127137A (zh) 2010-12-10 2011-07-20 郑州大学 制备雌甾氨基酸酯的中间体化合物及其合成方法
WO2015006691A1 (en) * 2013-07-11 2015-01-15 Evestra, Inc. Pro-drug forming compounds

Also Published As

Publication number Publication date
CO2020003537A2 (es) 2020-06-19
AU2018353858A1 (en) 2020-04-02
WO2019078983A1 (en) 2019-04-25
CL2020001028A1 (es) 2020-10-23
US20190117670A1 (en) 2019-04-25
BR112020007673A2 (pt) 2020-10-13
MX2020003470A (es) 2020-10-01
EP3697421A1 (en) 2020-08-26
ECSP20026239A (es) 2020-10-30
EP3697421C0 (en) 2024-04-17
US10624903B2 (en) 2020-04-21
EP3697421A4 (en) 2021-06-16
EP3697421B1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
PE20180227A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
HRP20231048T1 (hr) Derivati bipirazola kao jak inhibitori
BR112021019731A2 (pt) Composições para tratamento bucal para liberação de agente ativo
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
CY1124222T1 (el) Ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με μεθυλο/φθορο-πυριδινυλο-μεθοξυ και ενωσεις πυριδινονης-πυριδινυλιου υποκατεστημενες με φθορο-πυριδινυλο-μεθοξυ
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CL2017000979A1 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
AR101788A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
PE20150399A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BR112018072378A2 (pt) método, dispositivo de equipamento de usuário e rede móvel terrestre pública doméstica
BRPI0407329A (pt) Derivados de pirimidina para a prevenção de infecção de hiv
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
AR108659A1 (es) Composiciones no acuosas, no oleosas con bacillus amyloliquefaciens
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
PE20190609A1 (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTERICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
PE20181002A1 (es) Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana
BR112018011157A2 (pt) composição agroquímica de suspensão aquosa.
PE20210155A1 (es) Anticonceptivos de profarmacos de progestina de accion mas prolongada
PE20161415A1 (es) Derivados de etinilo
PE20191788A1 (es) Compuesto de n-(4-piridil)nicotinamida o sal del mismo
BR112017001123A2 (pt) bolsa de infusão de múltiplas misturas e método de utilização da mesma
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso
PE20180357A1 (es) Derivados de etinilo